Deals1 Oct 2025, 09:02 am
Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
AI Summary
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced a settlement and license agreement with Amgen Inc. that clears the path for the commercialization of Bosaya™ and Aukelso™, denosumab biosimilars, in the United States. The products are used in the treatment of osteoporosis and cancer-related bone conditions. The agreement enables BBL to launch BOSAYA and AUKELSO in the U.S. from October 1, 2025. The settlement also resolves the pending patent litigation at the United States District Court for the District of New Jersey.
Key Highlights
- Biocon Biologics secures U.S. market entry date for Bosaya™ and Aukelso™, denosumab biosimilars.
- The agreement resolves the pending patent litigation at the United States District Court for the District of New Jersey.
- BOSAYA and AUKELSO are biosimilars to Amgen’s Prolia® and Xgeva®, respectively, and are used in the treatment of osteoporosis and cancer-related bone conditions.
- The agreement enables Biocon Biologics to launch BOSAYA and AUKELSO in the U.S. from October 1, 2025.
- The settlement marks Biocon Biologics' entry into the bone health space, strengthening its oncology portfolio.